Jennison Associates
RCKT icon

Jennison Associates’s Rocket Pharmaceuticals RCKT Stock Holding History

Jennison Associates’s Portfolio RCKT Stock Details RCKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-114,580
Closed -$764K – 627
2025
Q1 		$764K Buy
114,580
+44,276
+63% +$437K ﹤0.01% 508
2024
Q4 		$884K Buy
70,304
+29,564
+73% +$445K ﹤0.01% 501
2024
Q3 		$752K Buy
40,740
+10,162
+33% +$208K ﹤0.01% 512
2024
Q2 		$658K Buy
30,578
+3,795
+14% +$87.2K ﹤0.01% 527
2024
Q1 		$722K Buy
26,783
+903
+3% +$25.6K ﹤0.01% 528
2023
Q4 		$776K Sell
25,880
-1,756
-6% -$38.8K ﹤0.01% 521
2023
Q3 		$566K Sell
27,636
-6,043
-18% -$110K ﹤0.01% 533
2023
Q2 		$669K Buy
+33,679
New +$680K ﹤0.01% 530
2018
Q1 		– Sell
-341,713
Closed -$3.57M – 695
2017
Q4 		$3.57M Sell
341,713
-47,466
-12% -$471K ﹤0.01% 507
2017
Q3 		$2.77M Buy
+389,179
New +$1.78M ﹤0.01% 521
2017
Q1 		– Sell
-495,211
Closed -$12.1M – 766
2016
Q4 		$12.1M Buy
495,211
+1,173
+0.2% +$33.5K 0.01% 465
2016
Q3 		$18.7M Buy
494,038
+6,941
+1% +$218K 0.02% 424
2016
Q2 		$14.5M Sell
487,097
-388
-0.1% -$13.6K 0.02% 438
2016
Q1 		$14.4M Buy
487,485
+7,522
+2% +$226K 0.02% 437
2015
Q4 		$21.8M Buy
479,963
+5,257
+1% +$229K 0.02% 415
2015
Q3 		$17.8M Buy
474,706
+106,092
+29% +$4.87M 0.02% 449
2015
Q2 		$7.22M Buy
368,614
+118,384
+47% +$2.62M 0.01% 529
2015
Q1 		$5.42M Buy
+250,230
New +$5.87M 0.01% 515

Other funds holding RCKT

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
NM
Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return

Jennison Associates's RCKT Position: Q2 2025 in Review

Jennison Associates sold out of Rocket Pharmaceuticals (RCKT) in Q2 2025, closing a stake of 114,580 shares — an estimated $764K sold.

Jennison Associates first reported a position in RCKT in Q1 2015 and held it in 18 quarters. The position peaked at $21.8M in Q4 2015. 196 funds tracked by Wall St. Rank hold RCKT as of Q2 2025.

  • Jennison Associates reported no remaining Rocket Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Jennison Associates sold 114,580 Rocket Pharmaceuticals shares in Q2 2025, an estimated $764K.
  • Jennison Associates first reported a position in Rocket Pharmaceuticals in Q1 2015 and held it in 18 quarters.
  • Jennison Associates's Rocket Pharmaceuticals position peaked at $21.8M in Q4 2015.
  • 196 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q2 2025.

Based on Jennison Associates's 13F filing for Q2 2025, filed 1 Aug 2025.